FindTrial
Sign In

Effect of nicotinamide riboside supplementation in dilated cardiomyopathy patients to CERP, Chromadex Inc. USA

Effect of nicotinamide riboside supplementation in dilated cardiomyopathy patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/04/051385
Enrollment
30
Registered
2023-04-06
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I43- Cardiomyopathy in diseases classified elsewhere

Interventions

Intervention1: nicotinamide riboside supplementation: 1000MG/DAY for 12 weeks Control Intervention1: Placebo: Vitamin C 1000MG/DAY for 12 weeks

Sponsors

Chromadex Inc. USA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Meeting criteria for dilated cardiomyopathy (DCM) : a. Left ventricular ejection fraction b. Left ventricular enlargement (A left ventricular end-diastolic dimension > 112% predicted value corrected for age and body surface area). c. Having conventional risk factors for DCM, including obesity, routinely treated hypertension, alcohol use, pregnancy or the peripartum period, or left ventricular noncompaction. 2. Any age (including children) 3. Ability to give informed consent

Exclusion criteria

Exclusion criteria: 1. Coronary artery disease (CAD) causing ischemic cardiomyopathy ( > 50% narrowing, any major epicardial coronary artery) 2. Primary valvular disease 3. Adriamycin or other cardiotoxic drug exposure 4. Other forms of cardiomyopathy: Hypertrophic, Restrictive, or Arrhythmogenic Right 5. Ventricular Dysplasia/Cardiomyopathy 6. Congenital heart disease 7. Other detectable causes of dilated cardiomyopathy, including sarcoid and hemochromatosis. 8. Other active multi-system disease that may cause DCM (e.g., active connective tissue disease). 9. Severe and untreated or untreatable hypertension 10. Absence of systemic hypertension( >160/100 mm Hg) 11. Pericardial diseases 12. Cor pulmonale

Design outcomes

Primary

MeasureTime frame
This study will serve as the first human clinical trial done in DCM patients using NR supplementation. Also this study will be one of a kind in evaluating the correlation of blood sirtuin and/or NAD+ concentration with DCM associated CHF progression.Timepoint: Day 0, 28, 56 and 84—

Secondary

MeasureTime frame
NATimepoint: NA—

Countries

India

Contacts

Public ContactBalamurugan Ramadass

AIIMS, Bhubaneswar

balaramadass1@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026